BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11165400)

  • 1. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis.
    Ueno K; Inoue Y; Kawaguchi T; Hosoe S; Kawahara M
    Lung Cancer; 2001; 31(2-3):213-9. PubMed ID: 11165400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
    Dudek AZ; Mahaseth H
    Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
    Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
    Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
    Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
    Ruotsalainen T; Joensuu H; Mattson K; Salven P
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1492-5. PubMed ID: 12433733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Ossolinska M
    Oncol Res; 2006; 16(1):49-54. PubMed ID: 16783968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
    Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
    Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
    Zhao J; Liu XY; Zhang QY; Jiang W
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.
    Isa S; Kawaguchi T; Teramukai S; Minato K; Ohsaki Y; Shibata K; Yonei T; Hayashibara K; Fukushima M; Kawahara M; Furuse K; Mack PC
    J Thorac Oncol; 2009 Sep; 4(9):1104-10. PubMed ID: 19620934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Hesselius P; Larsson A; Lamberg K; Wernlund J; Brodin O; Wagenius G
    Lung Cancer; 2002 Jul; 37(1):57-63. PubMed ID: 12057868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
    Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
    Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer.
    Brattström D; Bergqvist M; Hesselius P; Larsson A; Wagenius G; Brodin O
    Lung Cancer; 2004 Jan; 43(1):55-62. PubMed ID: 14698537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of serum Bcl-2 levels in advanced lung cancer patients.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
    Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer.
    Zhao W; Yu H; Han Z; Gao N; Xue J; Wang Y
    Int J Clin Exp Pathol; 2015; 8(8):9506-11. PubMed ID: 26464712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.
    Dietz A; Rudat V; Conradt C; Weidauer H; Ho A; Moehler T
    Head Neck; 2000 Oct; 22(7):666-73. PubMed ID: 11002321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
    Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.
    Garpenstrand H; Bergqvist M; Brattström D; Larsson A; Oreland L; Hesselius P; Wagenius G
    Med Oncol; 2004; 21(3):241-50. PubMed ID: 15456951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.